by The Tutu Team | Oct 10, 2016 | Uncategorized
Lung cancer trial results showed a win for Merck and a loss for Bristol-Myers. (tycoon101 – Fotolia/stock.adobe.com) Bristol-Myers Squibb (BMY) stock crashed to a two-year low Monday after competitor Merck (MRK) unveiled Phase 3 results showing lung-cancer drug... 